lanatosides and Disease-Models--Animal

This study investigated the effect of cedilanid on retinal neovascularization in a mouse model of oxygen-induced retinopathy.. Seven-day-old C57BL/6 mice were exposed to 75% ± 1% oxygen for 5 days and were then returned to room air to induce retinal neovascularization. Cedilanid (0.025-0.2 μg) was intravitreally injected into the left eye of each mouse on postnatal day 12 (P12) and P15. PBS was intravitreally injected into the right eye as a control. Retinal neovascularization was evaluated with isolectin GS-IB4 staining of the retinal blood vessels. The function of reestablishment blood vessels was evaluated with angiography with the injection of fluorescein isothiocyanate (FITC)-dextran followed by isolectin GS-IB4 staining. Real time (RT)-PCR and western blot were used to examine the mRNA and protein expression of hypoxia inducible factor 1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF), respectively.. Retinal neovascular areas and obliterative areas were statistically significantly smaller in the eyes injected with cedilanid (0.05 μg, 0.1 μg, and 0.2 μg) compared with the control eyes. The inhibitory effect of cedilanid was observed in a dose-dependent manner. In addition, the retinal neovascular areas and the obliterative areas in the eyes injected with 0.2 μg cedilanid on P12 were statistically significantly smaller than those in the eyes injected with the same dose of cedilanid on P15. Cedilanid promoted the circulative function of reestablished blood vessels in the obliterative areas. Cedilanid inhibited the expression of HIF-1α and VEGF in mice treated with hyperoxia.. Cedilanid inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy. Early treatment with cedilanid produces better inhibition of retinal neovascularization. Cedilanid may be a potential treatment of neovascular diseases.

Topics: Animals; Animals, Newborn; Disease Models, Animal; Dose-Response Relationship, Drug; Hypoxia-Inducible Factor 1, alpha Subunit; Lanatosides; Mice, Inbred C57BL; Oxygen; Retina; Retinal Neovascularization; Time Factors; Vascular Endothelial Growth Factor A

The tumor-tropic properties of neural stem cells (NSCs) have been shown to serve as a novel strategy to deliver therapeutic genes to tumors. Recently, we have reported that the cardiac glycoside lanatoside C (Lan C) sensitizes glioma cells to the anticancer agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Here, we engineered an FDA-approved human NSC line to synthesize and secrete TRAIL and the Gaussia luciferase (Gluc) blood reporter. We showed that upon systemic injection, these cells selectively migrate toward tumors in the mice brain across the blood-brain barrier, target invasive glioma stem-like cells, and induce tumor regression when combined with Lan C. Gluc blood assay revealed that 30% of NSCs survived 1 day postsystemic injection and around 0.5% of these cells remained viable after 5 weeks in glioma-bearing mice. This study demonstrates the potential of systemic injection of NSCs to deliver anticancer agents, such as TRAIL, which yields glioma regression when combined with Lan C.

Topics: Animals; Apoptosis; Brain Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Cell Movement; Coculture Techniques; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Genetic Therapy; Glioblastoma; Humans; Lanatosides; Mice; Mice, Nude; Neural Stem Cells; TNF-Related Apoptosis-Inducing Ligand; Transfection; Xenograft Model Antitumor Assays

Topics: Animals; Captopril; Disease Models, Animal; Dopamine; Female; Ferricyanides; Heart Failure; Hemodynamics; Lanatosides; Male; Myocardial Contraction; Nitroprusside; Rabbits